Arrowhead Pharmaceuticals, Inc.
ARWR
Rangering i aksjer
#2375
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Aksjekurs
$58.78
Markedsverdi
$8.30B
Endring (1 dag)
2.70%
Endring (1 år)
52.78%
Land
US
Handel Arrowhead Pharmaceuticals, Inc. (ARWR)
Kategori
Healthcare
Inntekter for Arrowhead Pharmaceuticals, Inc. (ARWR)
Inntekter i Jun 2026 TTM: $-252.08M
Ifølge Arrowhead Pharmaceuticals, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-252.08M. I 2024 hadde selskapet et resultat på $-612.46M, en nedgang sammenlignet med resultatet i 2023, som var $-206.49M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Arrowhead Pharmaceuticals, Inc. fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $-252.08M | -589.16% |
| 2025 | $51.53M | -108.41% |
| 2024 | $-612.46M | 196.60% |
| 2023 | $-206.49M | 19.56% |
| 2022 | $-172.71M | 22.62% |
| 2021 | $-140.85M | 66.58% |
| 2020 | $-84.55M | -224.07% |
| 2019 | $68.15M | -225.16% |
| 2018 | $-54.45M | 58.38% |
| 2017 | $-34.38M | -57.93% |
| 2016 | $-81.72M | -11.11% |
| 2015 | $-91.94M | 56.57% |
| 2014 | $-58.72M | 85.22% |
| 2013 | $-31.70M | 43.38% |
| 2012 | $-22.11M | 151.69% |
| 2011 | $-8.79M | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $-2.50M | 2,543.15% |
| 2003 | $-94.44K | -61.64% |
| 2002 | $-246.21K | 32.50% |
| 2001 | $-185.82K | 35.09% |
| 2000 | $-137.55K | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | -2,192.57% |
US
|
|
| $-3.09B | 1,124.62% |
US
|
|
| $-4.02B | 1,493.24% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -873.83% |
NL
|
